Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Azitra, Inc.
Azitra, Inc. will effect a 1-for-10 reverse stock split effective at 12:01 a.m. on October 26, 2026. Following this action, every 10 outstanding shares will be combined into one share, and the common stock is expected to begin trading on a split-adjusted basis at market open on October 26, 2026.…more
Azitra, Inc.
Azitra has successfully completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a treatment for EGFR inhibitor-associated skin rash, and received clearance from the safety review committee to proceed to Cohort 2. The company will now begin enrollment and dosing for approximately 24 patients in the second cohort, marking a significant milestone in addressing this debilitating side effect for cancer patients.…more
Azitra, Inc.
Azitra, Inc. entered into a sales agreement on September 28, 2026, with A.G.P./Alliance Global Partners to issue and sell common stock through an at-the-market (ATM) offering for up to $3,503,232. The company intends to use the net proceeds for working capital and general corporate purposes, with shares issued under an existing effective Form S-3 registration statement.…more
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Azitra Enters Sales Agreement For Up To $3.5M Common Stock Offering
Azitra has entered into a sales agreement with A.G.P. to offer up to $3.5 million in common stock. The potential for share dilution following this offering may impact existing shareholders.…more
●●●●●●●● ●●●●● ●●●●●●
Azitra has received notification from the NYSE American exchange confirming it has regained compliance with all continued listing standards. This development resolves the risk of delisting and allows the company to maintain its listing status.…more
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.